GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Ebglyss® | lebrikizumab-lbkz | MILR1444A | RG3637 | TNX-650
lebrikizumab is an approved drug (EMA (2023), FDA (2024))
Compound class:
Antibody
Comment: Lebrikizumab is a an anti-IL-13 monoclonal antibody.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. |
Classification ![]() |
|
| Compound class | Antibody |
| Approved drug? | Yes. EU EMA (2023) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 9165 | lebrikizumab |
Synonyms ![]() |
| Ebglyss® | lebrikizumab-lbkz | MILR1444A | RG3637 | TNX-650 |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 325 |
| Other databases | |
| GtoPdb PubChem SID | 223366019 |
| Search PubMed clinical trials | lebrikizumab |
| Search PubMed titles | lebrikizumab |
| Search PubMed titles/abstracts | lebrikizumab |
| Wikipedia | Lebrikizumab |